STAT reported that the Food and Drug Administration issued a de novo authorization to Powerful Medical’s Queen of Hearts algorithm, an artificial intelligence tool designed to analyze a standard 10-second EKG to support triage decisions for patients presenting with chest pain. The story places this authorization within a broader trend of AI devices cleared to detect arrhythmias and structural heart conditions from EKGs and imaging.
The accessible portion of the STAT article emphasizes the potential clinical role of AI at the point of care but does not include the full FDA decision text or the detailed clinical evidence submitted for the authorization in the excerpt provided.
STAT notes that most AI-based medical devices reach market via the FDA’s 510(k) clearance pathway. By contrast, the agency granted this product a de novo classification, a route used far less frequently. The article states that fewer than 10 devices receive de novo classification each year, and that the pathway typically entails more extensive clinical evidence than 510(k) clearance.
The source did not reproduce the de novo submission documents, labeling, or specific FDA conditions of authorization in the excerpt available.
According to the STAT piece, the algorithm aims to help triage patients who present with chest pain by identifying heart attacks that are harder to detect on routine EKG interpretation. The report frames the tool as a support for rapid decision-making about escalation of care, including identification of patients who may require urgent transfer to a cardiac catheterization laboratory.
The article does not provide the algorithm’s intended use statement, inclusion or exclusion criteria for patients, or any workflow examples showing how the output should be integrated into clinical practice.
STAT reiterates a foundational clinical point: the most severe myocardial infarctions occur when a coronary artery is completely occluded, producing ischemia that often manifests as ST-segment elevations on an EKG. Those patients usually require emergent reperfusion in a catheterization lab to restore blood flow and limit myocardial damage.
The article implies that Queen of Hearts is intended to detect presentations that may not show obvious EKG findings to the bedside clinician, though specific examples or case descriptions were not included in the excerpt.
The STAT report situates Powerful Medical’s algorithm within an expanding field of clinical AI cleared for cardiac applications: algorithms have already been cleared to screen for common arrhythmias and to flag structural heart conditions from EKGs or imaging. STAT also referenced AI models in development aimed at predicting risk of sudden cardiac arrest.
The article presents Queen of Hearts as another example of AI applied directly to acute cardiac diagnosis and triage, but it does not compare diagnostic accuracy, sensitivity, specificity, or intended clinical endpoints across devices in the excerpt.
The accessible STAT excerpt does not report the algorithm’s performance metrics, the size or composition of validation datasets, prospective trial results, clinician adjudication methods, or any postmarket surveillance commitments. It also does not provide information on manufacturer claims about false-positive or false-negative rates, or on any integration with EHRs or EKG machines.
Because the full article is behind STAT+, readers and clinicians should consult the FDA de novo decision documents or the manufacturer’s publicly available materials for specific clinical evidence and labeling information; those details were not reported in the source excerpt.
The reporting highlights potential benefits of AI-assisted EKG interpretation in acute care—more rapid recognition of patients who need emergent reperfusion could improve timeliness of care. At the same time, without published performance data in the excerpt, clinicians cannot assess how the algorithm alters diagnostic accuracy or workflow, or how it balances sensitivity and specificity in real-world settings.
Clinicians should look for the official FDA de novo summary, the product’s intended use statement, peer-reviewed validation studies, and any implementation guidance from the vendor before changing triage practices based on this device.
STAT’s coverage announces an FDA de novo authorization for Powerful Medical’s Queen of Hearts algorithm to help triage chest pain by analyzing EKGs, and places the decision in the context of increasing clinical AI for cardiovascular care. The accessible article excerpt provides regulatory context and high-level intent but omits the detailed clinical validation, performance metrics, and operational details that clinicians will need to evaluate the tool’s utility.
For full technical, clinical, and labeling information, consult the FDA de novo decision documentation and the manufacturer’s published materials; those specifics were not reported in the portion of the STAT article provided here.